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Abstract: Multiple sulfatase deficiency (MSD, MIM #272200) is an ultra-rare disease comprising
pathophysiology and clinical features of mucopolysaccharidosis, sphingolipidosis and other sulfatase
deficiencies. MSD is caused by impaired posttranslational activation of sulfatases through the
formylglycine generating enzyme (FGE) encoded by the sulfatase modifying factor 1 (SUMF1) gene,
which is mutated in MSD. FGE is a highly conserved, non-redundant ER protein that activates all
cellular sulfatases by oxidizing a conserved cysteine in the active site of sulfatases that is necessary for
full catalytic activity. SUMF1 mutations result in unstable, degradation-prone FGE that demonstrates
reduced or absent catalytic activity, leading to decreased activity of all sulfatases. As the majority
of sulfatases are localized to the lysosome, loss of sulfatase activity induces lysosomal storage of
glycosaminoglycans and sulfatides and subsequent cellular pathology. MSD patients combine clinical
features of all single sulfatase deficiencies in a systemic disease. Disease severity classifications
distinguish cases based on age of onset and disease progression. A genotype- phenotype correlation
has been proposed, biomarkers like excreted storage material and residual sulfatase activities do not
correlate well with disease severity. The diagnosis of MSD is based on reduced sulfatase activities
and detection of mutations in SUMF1. No therapy exists for MSD yet. This review summarizes the
unique FGE/ sulfatase physiology, pathophysiology and clinical aspects in patients and their care and
outlines future perspectives in MSD.
Keywords: multiple sulfatase deficiency; formylglycine-generating enzyme; lysosomal storage
disorder; posttranslational modification; sulfatases; glycosaminoglycans; sulfatides
1. Introduction
Multiple sulfatase deficiency (MSD; MIM #272200) is an ultra-rare disease caused by defective
activation of cellular sulfatases. Despite being the result of a single enzyme deficiency, MSD leads
to a failure of a group of enzymes involved in different cellular processes affecting lysosomes and
beyond [1–3] (Figure 1). Encoded by sulfatase modifying factor 1 gene (SUMF1), formylglycine
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generating enzyme (FGE), the deficient enzyme in MSD, drives a unique posttranslational modification
in newly synthesized sulfatases that is necessary for full catalytic activity.
Figure 1. Illustration of the mode of action of formylglycine generating enzyme (FGE). All cellular
sulfatases, most of which are localized in the lysosome, need posttranslational activation by FGE in the
endoplasmic reticulum (ER) through the conversion of conserved cysteines to formylglycine in their
active sites. Few proteins that interact with FGE in the ER and during its secretion upon overexpression
in the Golgi are known.
MSD affects 1 in 1.4 million newborns, and approximately 50 living individuals have been
identified [4]. From isolated case reports and publication of small cohorts of individuals, we have an
incomplete understanding of the complex phenotype and pathophysiology of MSD.
2. From a Variant Form of MLD to a Unique Posttranslational Modification and the Discovery of
the SUMF1 Gene
One of the sulfatases that MSD affects is arylsulfatase A, the defective enzyme in metachromatic
leukodystrophy (MLD). Not surprisingly, in 1965, MSD was initially described as a variant form of
MLD. In addition to low arylsulfatase A activities, the first described cases also demonstrated reduced
activities of different other sulfatases [5]. This was later defined to be a key diagnostic feature of
MSD [6,7].
Early attempts to improve the pathophysiology of MSD by genetic complementation of defective
or inactive sulfatases were unsuccessful [8–11]. This led to the hypothesis that a co-factor for sulfatases
or a posttranslational modification was missing in MSD. Evidence for a defect of posttranslational
modification arose from experiments demonstrating that expressed sulfatases introduced into MSD
cells by retroviral transduction were inactive [12]. In 1995, in a breakthrough study, Kurt von Figura
and colleagues discovered that sulfatases contain a crucial cysteine in the active site that needs
posttranslational oxidation to C-alpha formylglycine for full catalytic activity and that this modification
is missing in sulfatases expressed in MSD fibroblasts [13]. The identification of this unique and
sulfatase-specific modification initiated the search for the responsible enzyme which resulted in the
simultaneous, independent discovery of the formylglycine generating enzyme (FGE) and the sulfatase
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modifying factor 1 (SUMF1) gene in 2003 by two groups using different experimental approaches.
The group of Kurt von Figura purified FGE from microsomal fractions of bovine testis. The success of
this approach largely relied on the development of a mass spectrometry based FGE activity assay, in
which a synthetic peptide, encompassing residues derived from arylsulfatase A active site, served as
substrate. FGE activity in elution fractions was monitored for a shift in the mass of the peptide resulting
from the conversion of cysteine to formylglycine, until a pure protein could be referred to peptide
mass fingerprint analysis identifying bovine FGE leading to its human orthologue. Concurrently, the
group of Andrea Ballabio used a microsome-mediated chromosome transfer of human chromosomes
into an immortalized MSD fibroblast cell line, narrowing down the genomic location of the gene and
identified SUMF1 through mutation analysis in MSD fibroblasts. Both groups’ results were published
in 2003 [1,3].
3. FGE the MSD Protein
SUMF1, located on chromosome 3p26, is 106 kb long and contains 9 exons, and is ubiquitously
expressed with highest levels in kidneys and pancreas. Human FGE is a 40 kDa (374 residues)
glycoprotein localized in the endoplasmic reticulum (ER). Residues 1–32 constitute the cleavable
ER-signal sequence and the mature protein (residues 33–374) is N-glycosylated at asparagine N141.
The mature protein is organized into a core domain (residues 73–374) that harbors the active site and
an N-terminal extension (residues 33–72). FGE contains 8 conserved cysteines forming 2 disulfide
bridges, a pair of catalytically active cysteines in the active site, and a pair of cysteines in the N-terminal
extension [14,15]. In cultured cells, FGE is secreted and a major fraction of the secreted form is
devoid of this N-terminal extension. The N-terminal extension (residues 33–72) encoded by exon 1
of SUMF1 is a unique feature found only in FGE from higher eukaryotes and was shown to impart
two important functions via its two cysteins C50 and C52. Mutating these cysteines to alanine led to
loss of activation of sulfatases and loss of interaction with ERp44 for FGE retrieval back to the ER. For
unknown reasons, the N-terminal extension is cleaved off by the trans-Golgi-resident furin protease.
Other interacting partners ERGIC-53, ERp57 and PDI mediate ER retention, export and retrieval [16].
PDI is of special interest because it facilitates sulfatase activation through gatekeeping of proper FGE
folding (see below) [17]. FGE has an interacting paralogue protein pFGE, encoded by the SUMF2
gene that shares 47% percent of homology. pFGE is co-expressed with FGE in many tissues and binds
sulfatases but lacks catalytic function. A proposed function of pFGE is to help FGE activate sulfatase;
however, more evidence is needed to support this role [18–20]. The intracellular localization and
trafficking of FGE along the secretory pathway is considered to be a highly regulated process spatially
and temporally controlled by its interacting partners (Figure 1).
The FGE core protein exerts its enzymatic function on newly synthesized sulfatases co- or
post-translationally. FGE recognizes sulfatases by a linear sequence motif CxPxR as part of the putative
sulfatase signature I (C-STACG-P-STA-R-x(2)-LIVMFW) in the N-terminal catalytic domain. This motif
is evolutionary highly conserved and specific for recognition by FGE that converts the cysteine into a
sulfatase-specific amino acid, Cα-formylglycine (FGly) [14,21–23]. Introducing the CxPxR motif into
engineered proteins in cellular expression systems lead to FGly conversion by FGE and is used in a
variety of biotechnology applications [24,25].
Sulfatases are a group of enzymes that degrade or remodel sulfate esters. There are 17 sulfatases
encoded by the human genome, 13 of which have been characterized biochemically. The majority of
sulfatases are localized to the lysosome, while others are located in the ER, Golgi, or on the cell surface
(Table 1).
Int. J. Mol. Sci. 2020, 21, 3448 4 of 15
Table 1. Sulfatases affected in MSD, associated information and disease.
Sulfatase Alias Chromosomal Region Gene Localization Substrate Disease orSyndrome Abbreviation MIM No.
Arylsulfatase A Cerebroside-3-sulfatase 22q13.33 ARSA Lysosome Cerebroside-3-sulfate MetachromaticLeukodystrophy MLD 250,100
Iduronate-2-Sulfatase Xq28 IDS Lysosome HS, DS, H Hunter MPS II 309,900
Sulfamidase N-Sulfoglucosamine-sulfohydrolase 17q25.3 SGSH Lysosome HS, H Sanfilippo IIIa MPS IIIa 252,900
N-acetyglucosamine-
6-sulfatase 12q14.3 GNS Lysosome HS, H Sanfilippo IIId MPS IIId 252,940
Galactosamine-
6-sulfatase 16q24.3 GALNS Lysosome CS, KS Morquio A MPS IVa 253,000
Arylsulfatase B N-acetylgalactosamine-4-sulfatase 5q14.1 ARSB Lysosome CS, DS Maroteaux-Lamy MPS VI 253,200
Arylsulfatase G N-sulfoglucosamine-3-sulfatase 17q24.2 ARSG Lysosome HS
Usher syndrome type
4 USH4 618,144
Arylsulfatase K Glucuronate-2-sulfatase 5q15 ARSK Lysosome HS, DS unknown
Arylsulfatase C Steroidsulfatase Xp22.31 STS ER Steroid sulfates X-linked ichthyosis XLI 308,100
Arylsulfatase D Xp22.33 ARSD ER unknown
Arylsulfatase F Xp22.33 ARSF ER unknown
Arylsulfatase E Xp22.33 ARSE Golgi Chondrodysplasiapunctata type I CDPXI 302,950
Sulfatase 1 Sulf1 8q13.2-q.13.3 SULF1 Cell surface HS unknown
Sulfatase 2 Sulf2 20q13.12 SULF2 Cell surface HS unknown
Arylsulfatase H Xp22.33 ARSH unknown unknown
Arylsulfatase I Sulf5 5q32 ARSI unknown unknown
Arylsulfatase J Sulf4 4q26 ARSJ unknown unknown
HS: Heparansulfate, DS: Dermatansulfate, KS: Keratansulfate, CS: Chondroitinsulfate, H like component.
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Sulfatase substrates comprise glycosaminoglycans (GAGs), sulfolipids, and steroid
hormones [26,27]. In addition, sulfatases exert important regulatory roles on heparan sulfate-dependent
cellular signaling pathways [28,29]. High specificity for substrates leads to low redundancy by different
sulfatases, as such single sulfatase deficiencies result in severe disorders, most of which are lysosomal
disorders [26]. No redundant FGly generating mechanism exists in mammals, and FGE is a limiting
factor for sulfatase activation. A complete loss of SUMF1 or FGE function results in decreased activity
of all sulfatases rendering MSD a monogenetic disease [1,3]. The requirement of FGly generation
by FGE for catalytic activity of sulfatases has prompted the co-expression of FGE in the production
process of recombinant sulfatases for enzyme replacement therapy as well as gene-therapy approaches
for single sulfatase deficiencies [30–34].
The role of FGEs secreted form is unknown. A paracrine function has been discussed because of its
cellular uptake followed by FGE reaching the ER and exerting sulfatase activation [35,36]. This renders
FGE to be one exceptional example of a protein reaching the ER after endocytosis, a mechanism known
from toxins or viruses [37]. Further experimental evidence is needed before recombinant FGE could
eventually be used for ERT as a therapy for MSD.
Recently, another mechanism of regulation for FGE activity has been proposed: miRNA-95
depletes FGE and results in decreased sulfatase activities leading to impaired lysosomal function,
substrate accumulation and a block of autophagy. Lowering the levels of miRNA-95 in MSD patient
cells restored sulfatase function exerting a therapeutic potential [38].
The crystal structure of FGE has been established in 2005 and allows insight into FGEs mode of
action as well as modelling changes on its structure by MSD causing SUMF1 mutations [14,39]. FGE
has a unique fold with low amount of secondary structure (13% α-helices, 20% β-sheets). Stabilization
occurs via disulphide bridges (see above) and two calcium ions. The crystal structure suggested
FGE to be a mono-oxygenase as FGly generation consumed equimolar levels of molecular oxygen
although no redox active metal ions could be detected [14]. For over a decade, FGE was regarded as a
metal-independent mono- oxygenase.
However, an increase in the activity of FGE after in vitro reconstitution with Cu2+, led to the
proposal that FGE utilizes copper as a cofactor [40–42]. Recently, the crystal structures of two
prokaryotic FGE-holoenzymes reconstituted with Cu from Streptomycis coelicolor and Thermomonospora
curvata were reported [43,44]. Both structures revealed that a Cu(I) atom is coordinated by two active
site cysteine residues in a nearly linear geometry, unusual for copper-dependent oxidases. Based
on structural and biochemical data, a structural basis for oxygen activation by the catalytic copper
center via a Cu(II) superoxo-intermediate was proposed, thus providing mechanistic insights into FGly
generation by FGE and activation of sulfatases.
4. SUMF1 Mutations and Functional Consequences
Fifty-three SUMF1 mutations have been published in the literature since the discovery of the
SUMF1 gene including 21 nonsense mutations (frameshift, stop-gain, deletions), and 32 missense
mutations distributed over the entire length of the protein (Figure 2).
Functional consequences of SUMF1 mutations on the FGE protein have been analyzed for a subset
of mutations using a combination of in silico and in vitro biochemical methods. Crystallization of the
FGE protein facilitated in silico modelling of amino acid exchanges and prediction of FGE stability and
activity especially when variants affect the active site of FGE [14,39]. In vitro experimental data were
generated for a subset of mutations using different experimental approaches. Analysis of endogenous
FGE levels in patient derived fibroblasts provided information on protein stability and subcellular
localization. Pulse-chase experiments of cell lines expressing variant FGE constructs have been used to
determine protein half-life for a variety of SUMF1 variants [45].
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Figure 2. Fifty-three published SUMF1 mutations. Nonsense mutations (lower panel) and missense
mutations displayed as amino acid changes in FGE (upper panel) and their localization on FGE. Exons
encoding respective parts of the amino acid chain as well as regions forming the signal peptide, the
N-terminal extension and the core domain with the active site are labelled. Mutations are distributed
all over the entire length of the FGE amino acid chain without obvious hotspots.
In addition to impaired protein stability, FGE enzymatic activity is affected by clinically relevant
SUMF1 mutations. FGE activity is best assessed through the measurement of sulfatase activities at
endogenous levels in patient cells or by co- expression of indicative sulfatases and sulfatase activity
assays in cell models [45–50]. A well-established assay uses bi-directional co-expression of steroid
sulfatase and FGE from an inducible vector proven to yield highly reproducible and comparable
sulfatase activities referring to FGE activity [51]. Apart from the mass spectrometry-based assay
described above, currently there is no assay available for direct FGE activity measure ent. Although
this approach requires partially purified variant FGE, it has been used for FGE activity determination
for a subset of variant FGE proteins [45,50].
The majority of SUMF1 mutations are of hypomorphic nature resulting in expression of FGE with
residual activity [46]. Only nonsense mutations completely abrogate FGE function [52]. All previously
analyzed mutations demonstrated reduced intracellular protein levels and excretion supporting the
hypothesis that most variants result in early degradation and/or reduced stability of FGE [45–48,50,52].
In fact, the majority of FGE variants analyzed demonstrate a half-life of less than 2 h [45,49–51].
Residual FGE activity of variant proteins was variable ranging from complete loss of activity
in active site mutations to 50% of reference activity [45,49,50]. Of note, 1/3 of all published SUMF1
mutations lack experimental data on stability and activity. Disease causing variants of FGE likely
disrupt function through overall instability and decreased enzymatic activity.
Data are beginning to come up on the intracellular fate of variant FGE species. Protein disulfide
isomerase (PDI) was shown to interact with wild type FGE and co-expression of PDI improved
activation of sulfatases. This led to the suggestion that PDI could play a role in improving proper
folding of wildtype FGE [16]. However, PDI was shown to preferentially interact with misfolded
variant FGE, which established isfolded variant FGE as a physiological substrate for PDI [17].
Moreover, the crucial function of PDI as a disease modifier in MSD emerged when it was shown to play
a role in variant FGE stability and residual activity. In vitro, overexpression of PDI reduces residual
sulfatase activities, while PDI silencing rescues sulfatase activities by increasing variant FGE stability.
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Downstream effects of FGE deficiency and sulfatase dysfunction are only partially understood
in MSD, and only a limited number of studies have explored the pathophysiology of disease. As
part of the MSD phenotype, glycosaminoglycans (GAGs) and sulfatides accumulate, as is seen in
mucopolysaccharidoses (MPS) and MLD. This abnormal storage results in lysosomal dysfunction,
impacting several cellular processes including autophagy [53]. Many pathophysiological aspects
proposed for lysosomal dysfunction, e.g., membrane turnover, calcium storage or mTORC1 function,
have not been explored in MSD [54]. Effects caused by the remaining uncharacterized sulfatases are
yet to be determined.
5. Clinical, MRI, and Ultrastructural Features, Disease Classifications, Genotype-Phenotype
Correlation
MSD is a complex disease because it combines symptoms of single sulfatase deficiencies. It is a
progressive, systemic, neurodegenerative disorder of early childhood. The majority of individuals
with MSD present with systemic features and psychomotor retardation followed by loss of motor skills,
speech, hearing, and vision. Many individuals also have characteristic facial features consistent with
MPS disorders, chondrodysplasia punctata, hepatosplenomegaly, and ichthyosis (Figure 3A–C). While
all individuals with MSD have neurologic impairment, the other systemic features can be variable
and are often not present at birth [45,48,50]. Additional symptoms include cardiac defects, pulmonary
involvement, recurrent ear infections, sleeping disorders, hydrocephalus, corneal clouding, retinitis
pigmentosa, and hydrops fetalis. Sleep disturbance, feeding difficulties, constipation, spasticity, and
hip dislocation are frequent symptoms that affect quality of life. Some patients failed in newborn
hearing screening tests. MRI findings can also be variable with demyelination resembling MLD,
brain atrophy, corpus callosum hypoplasia, subcerebellar cysts, and hydrocephalus [55] (Figure 3D,E).
Ultrastructural findings comprise pleomorphic lysosomal inclusions in Schwann cells detected in skin
biopsies, and reduced germ size and hypomineralized enamel in teeth. Brain tissue analysis revealed
pleomorphic extracellular, intraneural, and intraglial inclusions and white matter showed gliosis and
metachromasia [56–58].
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Similar to other lysosomal storage disorders, MSD can be divided into neonatal, late infantile and
juvenile forms based on age at onset [59]. Revisions of this classification added gradations of disease
severity to the age of onset subtypes. While early onset of disease is associated with the most severe
forms, it is unknown if how well these subtypes associate with overall clinical outcomes.
Children with early onset disease, the neonatal form, are characterized by presence of multiple
MSD-related symptoms at birth. Late infantile cases, which are divided into severe and mild forms,
present symptoms in infancy. The latter shows a reduced number of symptoms and a later onset,
especially of neurodegeneration and neurological symptoms, and slow acquisition of additional
symptoms [45,48,50]. Juvenile MSD is the most rare and the most attenuated form [60].
While these classifications are still in use, there are several limitations to their clinical utility. Upon
deeper medical history review, many individuals with an attenuated form of MSD presented with a
limited number of symptoms in the neonatal period. These early symptoms often include failure to
thrive with feeding difficulties, inguinal hernias, and hypotonia. Based on the existing classification
system, these individuals would qualify as neonatal form MSD by onset, but as juvenile or late infantile
by clinical course. Clearly, there is a need to define clinically coherent subtypes of MSD that are based
on our modern, deeper understanding of the clinical course of MSD [45,48,50].
Sulfatase activities in patient fibroblasts have been used for an alternative, historical disease
classification in MSD: Group I fibroblasts exhibit residual activity below 15% of control activity
measured in fibroblasts from non-MSD patients. Group II fibroblasts show more than 15% of residual
activity, sometimes reaching normal values. Group I fibroblasts derive from severe MSD cases whereas
group II fibroblasts originate from attenuated MSD cases [52,56,61–63]. Interestingly, and in contrast to
group I fibroblasts, group II fibroblasts were reported to show variable sulfatase activity over time in
the same cell line. Such cells are likely influenced by cell culture conditions and culture time [61,64].
The mechanisms underlying sulfatase activity variation are unknown. The number of MSD fibroblast
cell lines that have been investigated are limited, impairing our full understanding of sulfatase activity
fluctuations. However, subsequent publications have supported that a subset of patients could have
variable sulfatase activities overtime [48].
Despite the difficulties in establishing a reliable disease classification, the clinical course of MSD
falls into two categories: Severe and attenuated. Further work is needed to associate these clinical forms
with other features of the disease. There is emerging evidence for a genotype–phenotype correlation
in the homozygous form of the disease. Patients with biallelic nonsense mutations have the most
severe symptoms and often have absent sulfatase activities (severe or neonatal very severe form) [52].
Attenuated patients often harbor variants that result in a highly unstable variant FGE with low residual
activity. Milder attenuated patients can have unstable FGE variants with high residual activity or stable
FGE variants with low residual activity. This preliminary genotype–phenotype correlation allows for a
rough prediction of the course of disease in cases with homozygous SUMF1 mutations that have been
experimentally assessed [45,48,50]. A genotype–phenotype correlation in compound heterozygous
patients has not been fully investigated and is an area of active interest.
6. Biomarkers and Diagnosis
Disease specific biomarkers for MSD exploit the biomarkers developed for the related lysosomal
disorders. This includes measurements of sulfatase activities, urinary sulfatides, and glycosaminoglycan
accumulation. The simultaneous excretion of heparan sulfate, dermatan sulfate, keratan sulfate and
chondroitin sulfate is strongly suggestive of MSD. Interestingly, increased GAG excretion is absent in
some MSD patients [48] and the factors contributing to such negative GAG measurements in MSD
patients are poorly understood.
Sulfatase activities are low in MSD patients, but levels can vary over time, even in the same
individual. Also, since sulfatase activities are very dependent on the biochemical assay design,
comparing results obtained in different laboratories is difficult [63,65]. In short, a detailed understanding
of the association between specific SUMF1 variants and biochemical phenotypes are lacking. Historically,
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the clinical diagnosis of MSD was confirmed by measuring simultaneous deficiency of more than one
sulfatase activity in patient leukocytes or fibroblasts. Nowadays, SUMF1 genetic testing supports the
diagnosis of MSD. With the advancement of broad based, non-targeted sequencing (next-generation
sequencing panels, exome and genome sequencing), it is likely that novel SUMF1 mutations will be
found and the phenotypic spectrum will also evolve.
However, it has to be noted that both biochemical and genetic confirmation have a risk of false
negative results. MSD could be missed on panels that measure limited sulfatases, for example, when
a test measures only two sulfatases, one could be abnormal and the other normal. In theory, cases
could be misdiagnosed as MSD due to arylsulfatase A pseudodeficiency, which is a biochemical
artefact of in vitro testing. Sanger sequencing of genomic SUMF1 could miss large deletions expanding
into or spanning the complete SUMF1 gene. Also, as MSD is so rare, it is possible that pathogenic
variants could be mislabeled as variants of unknown significance. Given these diagnostic challenges,
we recommend a combination of genetic and biochemical testing with the measurement of at least
three sulfatases.
7. Care of MSD Patients
No curative therapy is currently available for MSD. MSD patients often face multiple health
problems due to the complexity of the disease. As a result from the first International Conference on
MSD (Dublin, July 2017) a consensus statement on the complex care and management of MSD patients
was published providing the first clinical guidelines for MSD [55]. The consensus statement outlines a
standardized framework for comprehensively addressing clinical problems and the management of
symptoms in MSD. These guidelines summarize a list of initial evaluations that should be considered
in every newly-diagnosed MSD patient to assess for the major clinical complications that have been
reported on this rare disease. This includes evaluation of 10 different organ systems, each with a variety
of potential complications (Table 2). This comprehensive list of potential interventions needs to be
individualized based on the patient and institutional experience. An expert-driven multidisciplinary
approach with goal of a high quality-of-life for the affected individuals and also the care-givers should
be the primary objective of care [55].
Table 2. Clinical care of MSD patients-systems-based approach.
System Clinical Concerns
Cardiac and vascular Arrythmias
Cardiac hypertrophy
Cardiac valve issues
Hypertension
Dermatologic Hirsutism
Ichthyosis
Musculoskeletal Cord compression
Dysostosis multiplex
Poor bone health
Tone abnormalities
Neurologic Peripheral neuropathy
Hydrocephalus
Intracranial pressure
Seizures
Nutrition and gastroenterologic Feeding intolerance
Constipation
Hepatosplenomegaly
Gastroesophageal reflux
Gallbladder issues
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Table 2. Cont.
System Clinical Concerns
Ophthalmic Cataracts
Corneal clouding
Glaucoma
Retinopathy
Retinitis pigmentosa
Optic nerve abnormalities
Strabismus
Oral Dental complications
Hyperplastic gums
Poor oral- motor coordination
Tooth enamel abnormalities
Otolaryngologic Airway obstruction
Airway narrowing
Oral and pharyngeal obstruction
Hearing disorders
Recurrent otitis media
Respiratory Obstructive and recessive lung disease
Sleep issues
Apnea (central and peripheral)
Recurrent pneumonia
8. MSD Animal Disease Models
A SUMF1 gene-trap knock-out mouse (SUMF1gt) was the first MSD animal model. Homozygous
SUMF1gt mice displayed absence of eight sulfatase activities tested and storage of glycosaminoglycans
in macrophages, kidney and liver. Mice showed signs of head tremor, seizures, skeletal abnormalities
and a flat facial appearance. All had congenital growth retardation and more than 90% of SUMF1gt mice
died prior to 3 months of age. The mice demonstrated significant systemic and neuroinflammation,
indicated by activated microglia, astrocytosis and neuronal loss [66]. Furthermore, fibroblast growth
factor signaling was constitutively activated in SUMF1 knock-out mice derived hematopoietic stem
cells and hematopoietic stem progenitor cells resulting in a block in erythroid differentiation, disruption
of B lymphocyte differentiation, reduction in mature myeloid cells and aberrant T lymphocyte
development [67]. Astrocyte specific knock-out of SUMF1 in a Cre/Lox MSD mouse model revealed
lysosomal storage of substrates and autophagy substrates impairing astrocyte function. This led to
neuronal loss thereby highlighting the importance of astrocyte dysfunction in the pathophysiology of
MSD [68].
The SUMF1gt mouse model has also been used for the first MSD treatment approach: Combined
intraventricular and systemic administration of a recombinant adeno-associated virus type 9 (rAAV9)
encoding FGE resulted in a widespread transduction of different tissues followed by an increase of
sulfatase activities, clearance of glycosaminoglycans and decrease of inflammation. rAAV9SUMF1
treated mice also showed improved behavioral issues. These results suggest that gene therapy might be
a treatment option in MSD [69]. Additional mouse models harboring common human SUMF1 variants
are currently being generated and characterized. These tools can be used to evaluate novel therapies
aimed at correcting misfolded FGE species or increasing lysosomal performance and clearance abilities.
The high evolutionary conservation of SUMF1/FGE has allowed for the establishment of additional
animal models. A drosophila melanogaster SUMF1 knock out fly and SUMF1 knock out zebrafish lines
are currently being characterized. Both models can be used to study early embryonic development in
MSD and could also prove useful to future drug screening efforts.
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9. Patient Organizations and Research Towards a Therapy for MSD
Independently two patient organizations were founded in 2015 by parents with children affected
by MSD. MSD Action foundation in Ireland and United MSD Foundation in the US have become
drivers in collaborative efforts to improve the clinical care and research options for children with MSD.
Since the founding work of these important organizations, two more national patient organizations
were founded in Spain and Argentina. Patient organizations have a major impact on basic and clinical
research for rare diseases by connecting researchers, clinicians and patients, offering grants for research
towards therapy and running patient registries [70]. Social networks connect patients and families with
rare diseases globally and facilitate efforts to make rare diseases known to the general public [71,72].
Like other rare diseases, comprehensive natural disease history data on MSD is lacking. Current efforts
are underway to better define the clinical course of MSD around the world. Results from these projects
will serve as a basis for defining natural disease history and clinical endpoints in anticipation of clinical
trials in the near future.
10. Future Perspectives
Given the growing interest in the science of MSD and awareness of the disease in general, we
anticipate that our understanding of MSD will also continue to develop. The search for additional
interacting partners of FGE that regulate enzymatic function, folding, trafficking and degradation will
elucidate novel aspects of cell biology. All newly discovered interacting proteins and pathways have
the potential of serving as targets for the development of MSD therapy.
In terms of clinical knowledge, definitions of MSD will be informed by ongoing and future
natural disease history studies. Such studies may further our understanding of factors that determine
disease severity, clarify genotype-phenotype relationships, and reveal biomarkers that can be used to
track disease progression. Finally, as newborn screening for single sulfatase disorders and genomic
sequencing are more widely utilized, new MSD patients will be identified that will likely expand the
MSD phenotype.
The exciting recent progress in MSD research represents the synthesis of basic science and clinical
medicine with patient advocacy. As this foundation of knowledge grows, our hope is that potential
treatment options will be developed. The growing understanding of the pathophysiology of the disease
and generation of the MSD animal models, will set the stage for exploring potential treatment options,
design potential therapeutic agents and serve as tools for pre-clinical therapy evaluation and testing.
Also, one can expect that meaningful clinical endpoints derived from natural disease history data will
aid clinically-relevant trial design. It is crucial that for an ultra-rare and orphan disease like MSD, any
therapeutic strategy that ameliorates the disease condition would greatly improve the lives of MSD
patients and their families.
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